By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
The panel consensus is bearish on IonQ, with key concerns being high valuation, significant dilution, and the risk of 'quantum winter' by 2026-27.
Risk: The risk of 'quantum winter' by 2026-27, where government funding pivots to alternative architectures, rendering IonQ's current trapped-ion capital expenditure entirely sunk.
Opportunity: Meaningfully improving margins and winning a larger, steadier government/cloud footprint.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
IonQ’s trapped-ion business is booming.
But its high valuations could limit its near-term gains.
IonQ (NYSE: IONQ), one of the early movers in the nascent quantum computing market, grew its revenue from just $2 million in 2021 to $130 million in 2025. That made it the first pure-play quantum computing to generate over $100 million in annual revenue, and its stock surged nearly 550% over the past five years. Could it soar another 50% and hit $100 this year?
Quantum computers can process specific tasks much faster than classical computers, but they're also larger, more expensive, consume more power, and output more errors. Quantum computing companies are also using a wide range of different technologies, which fragment the market and limit its growth potential beyond niche research applications.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Most quantum computing companies accelerate electrons through superconducting loops to process data. These systems are becoming cheaper to manufacture as the technology matures, but they're large and require cryogenic refrigeration. IonQ addresses those issues with its trapped-ion systems, which trap individual ions and manipulate them with lasers. These systems can operate at room temperature and have lower error rates than electron systems.
IonQ has launched four quantum systems, and it sells and leases them to research institutions. It also acquired seven smaller companies over the past five years. Yet most of its revenue still comes from its cloud-based quantum computing platform, which gives customers remote access to its own quantum systems.
IonQ's growth in government contracts, which prompted it to create its new IonQ Federal division in 2025, drove most of its recent expansion. From 2025 to 2028, analysts expect its revenue to grow at 70% CAGR to $638 million as the business fires on all cylinders.
IonQ's business is booming, but it's still unprofitable and looks richly valued at 40 times its 2028 sales. If its market cap swells 50% to $38.3 billion, it would trade at 60 times its 2028 sales. Therefore, I'm not expecting IonQ's stock to hit $100 by the end of this year.
It had a great run, but its business needs to grow into its sky-high valuations. Its share count has nearly doubled since its public debut in Oct. 2021, and it will likely continue to dilute its investors through stock-based compensation and secondary offerings as long as its cash flow remains negative.
That might be why IonQ's insiders sold seven times as many shares as they bought over the past 12 months. While IonQ's technology is promising and its business is growing rapidly, there's a bit too much optimism baked into its high-flying shares in this frothy market.
Before you buy stock in IonQ, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and IonQ wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $439,632! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,316,532!
Now, it’s worth noting Stock Advisor’s total average return is 959% — a market-crushing outperformance compared to 210% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of June 4, 2026. *
Leo Sun has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends IonQ. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"IonQ's trapped-ion platform, reinforced by government contracts and cloud-based recurring revenue, could justify a multi-year re-rating even if near-term profitability lags."
IonQ’s revenue milestone (over $100m in 2025) shows real customer traction, and the 2025–2028 forecast to $638m (70% CAGR) hints at durable growth from government and cloud channels. But the stock trades at rich multiples (about 40x 2028 sales; 60x if cap rises 50%), while profitability remains elusive and dilution looks ongoing with stock-based comp and potential secondary offerings. The piece omits volatility in government budgets, customer concentration, and execution risk as IonQ scales production of four systems. If IonQ can meaningfully improve margins and win a larger, steadier government/cloud footprint, the equity could re-rate; otherwise, multiple compression is plausible.
The 2028 targets imply an unsustainably high multiple unless margins leap; ongoing dilution, heavy cap-table expansion, and potential capital raises could crush short-term returns, and government-contract cadence adds execution risk.
"IonQ is priced for a near-certainty of dominance that the underlying technical risks and persistent share dilution do not justify."
IonQ’s revenue growth is impressive, but the valuation is detached from operational reality. Trading at 40x forward 2028 sales is an aggressive bet on perfect execution in a nascent, capital-intensive industry. While trapped-ion technology offers a theoretical advantage in error rates and cooling, the company remains a cash-burning machine with significant dilution risk. The reliance on government contracts is a double-edged sword; it provides stability but limits margin expansion compared to commercial scaling. Investors are currently pricing in a 'winner-take-all' scenario in quantum computing, ignoring the reality that this market will likely remain fragmented and highly competitive for the next decade.
If IonQ achieves a breakthrough in quantum error correction that allows for practical, fault-tolerant commercial applications, their current valuation could look like a bargain compared to the massive addressable market they would unlock.
"IonQ's 70% CAGR is priced in at 40x forward sales; the stock needs either a margin inflection or a 2x TAM expansion just to justify current multiples, neither of which is guaranteed."
IonQ's 70% revenue CAGR through 2028 is impressive, but the valuation math is broken. At 40x 2028 sales today, the stock prices in flawless execution AND sustained hypergrowth beyond 2028. The article buries the real problem: negative cash flow, dilution, and insider selling (7:1 ratio) signal management doesn't believe in these valuations. Government contracts are lumpy and cyclical—not a durable moat. The trapped-ion tech advantage is real, but competitors (Atom Computing, IonQ's own customers) are closing the gap. Revenue growth without profitability is a treadmill, not a thesis.
If IonQ captures even 30% of an emerging $50B+ quantum-as-a-service market by 2030, today's valuation looks cheap on a TAM-adjusted basis, and government contracts could provide recurring, defensible revenue that justifies premium multiples.
"Persistent dilution and government-heavy revenue leave IonQ vulnerable to valuation compression despite headline growth."
IonQ's trapped-ion edge and 70% CAGR to $638M by 2028 rest heavily on government contracts via its new Federal division, yet the article downplays execution risk in scaling error-corrected systems for commercial use. Current 40x 2028 sales valuation already embeds aggressive assumptions; further dilution from negative cash flow and doubled share count since 2021 could cap upside even if revenue hits targets. Insiders' 7:1 sell-to-buy ratio signals caution on near-term re-rating.
A single large commercial contract or error-rate breakthrough could accelerate adoption timelines and justify multiples well above 40x if quantum moves from research to enterprise workloads faster than expected.
"Without meaningful margin expansion and unit-cost reductions to support a sustainable re-rate, IonQ's current 40x 2028 sales multiple is just a bet on execution that may not materialize."
Claude's focus on dilution and cash burn is valid, but the harsher reality is scaling cost and yield for error-corrected systems remains the wild card. A multi-year gov/enterprise backlog could provide visibility, but without clear, tangible margin uplift or unit-cost declines, the 40x 2028 sales multiple looks like a bet on perfect execution beyond 2028. The panel should quantify required margin inflections and capex cadence to reach a sustainable re-rate.
"Insider selling is a standard byproduct of talent acquisition in deep tech, whereas the real existential threat is technological obsolescence if IonQ misses its 2026 fault-tolerance milestones."
Claude, your focus on insider selling is a red herring; in pre-revenue deep tech, equity-based compensation is the primary currency for talent retention, not necessarily a signal of management's lack of conviction. The real risk is the 'quantum winter' threat: if IonQ fails to demonstrate a clear path to fault-tolerant utility by 2026, government interest will pivot to alternative architectures like superconducting or photonic qubits, rendering IonQ's current trapped-ion capital expenditure entirely sunk.
"Quantum winter risk by 2026–27 is underpriced relative to the 40x 2028 sales multiple and should dominate the valuation conversation."
Gemini's 'quantum winter' risk is the hardest variable to price and deserves more weight. If fault-tolerant utility doesn't materialize by 2026–27, government funding pivots to competing architectures, and IonQ's trapped-ion moat evaporates regardless of revenue growth. That's not execution risk—it's existential. The 40x multiple assumes this doesn't happen. Nobody quantified the probability or timeline for that inflection point.
"Dilution compounds the quantum winter timeline risk by forcing recapitalization before any re-rating."
Claude correctly flags the 2026-27 fault-tolerance deadline as existential, yet the bigger unpriced threat is how cumulative dilution from 2021's doubled share count compounds if that deadline slips even modestly. Each year of negative cash flow at current burn rates risks a forced equity raise that resets the valuation baseline before any revenue re-rating materializes, regardless of architecture wins.
The panel consensus is bearish on IonQ, with key concerns being high valuation, significant dilution, and the risk of 'quantum winter' by 2026-27.
Meaningfully improving margins and winning a larger, steadier government/cloud footprint.
The risk of 'quantum winter' by 2026-27, where government funding pivots to alternative architectures, rendering IonQ's current trapped-ion capital expenditure entirely sunk.